TruthArchive.ai - Related Video Feed

The speaker's administration will implement "most favored nations" drug pricing, ensuring Americans pay the lowest price for drugs compared to other developed countries. Some prescription drug prices will be reduced almost immediately by 50% to 90%. Big Pharma must voluntarily comply or the federal government will ensure equal pricing. To accelerate price reductions, the administration will cut out the middlemen to facilitate direct drug sales to American citizens at the most favored nation price. The speaker believes the middlemen are worse than drug companies because they don't make a product but make a fortune.

One breast cancer drug costs over $16,000 per bottle in America. The same drug, from the same factory and company, costs one sixth the price in Australia. In Sweden, the identical product costs one tenth the American price.

A businessman told the speaker that the same fat shot drug cost him $88 in London, but $1,300 in New York. He was stunned that the identical pill, made in the same plant by the same company, had such different prices. The speaker discussed this with drug company representatives. They argued for about half an hour, but ultimately the representative admitted there was no justification for the price difference.

The speaker claims the United States spends $1,126 per capita on drugs, while Britain spends about $240, approximately one-fifth of the U.S. figure, a trend seen across Europe. The speaker says drug companies claim America must pay for pharmaceutical innovation. President Trump is quoted as saying European partners need to increase their drug payments to cover their share of innovation, asserting the U.S. should no longer subsidize it. The speaker concludes that if Europeans raised drug prices by 20%, the resulting $10 trillion could be spent on innovation, improving global health.

Speaker contrasts health care in the US and Italy. They state that 'doctors in The US will prescribe antibiotics at any chance they can,' while noting that their boyfriend in Italy was sick and 'he went to his doctor, and his doctor told him to get rest and drink some milk before bed.' They ask, 'I'm sorry, but where is that information in The US?' and describe the difference as 'crazy to me the difference that we see between health care in America versus health care in Italy,' adding that this is 'one tiny example of how the system works in America versus Italy.' The remarks illustrate a perceived disparity in how health care systems operate across the two countries.

Brenzavvy, a drug similar to Jardiance or Farxiga, is not covered by insurance, prescribed by doctors, or carried by wholesalers because it is too cheap. Brenzavvy costs $60 at the speaker's pharmacy. Pharmacy benefits managers (PBMs) deny coverage because Brenzavvy's low price prevents rebates. Farxiga and Jardiance cost insurance payers $1,000 upfront with a 40% rebate. An HHS report stated PBMs get 23% on average for brand meds. After rebates, Farxiga and Jardiance still cost $600, with PBMs earning $138. With 8,000,000 prescriptions a year, PBMs make $1,100,000,000 off those two drugs. The speaker claims PBMs keep Brenzavvy off their lists to avoid losing a billion dollars annually. The speaker believes affordable healthcare is impossible with PBMs involved. The speaker encourages listeners to use forestpark.pharmacy to save money and to inform their bosses about potential savings.

The speaker states they capped prescription medication costs at $2,000 annually for seniors and insulin costs at $35 for seniors. They highlight that Black individuals are 60% more likely to be diagnosed with diabetes. The speaker claims that another plan would eliminate the insulin cost cap.

Pharmaceutical companies generate over two-thirds of their profits in the United States, despite the U.S. accounting for only 4% of the world's population. The speaker expresses respect for pharmaceutical companies and their leadership. They believe these companies successfully convinced people for many years that the current system was fair, even though the reasons why were not widely understood.

Pharmaceutical companies claimed research and development costs had to be borne by America alone, which effectively meant American patients were subsidizing socialist healthcare systems in places like Germany and the European Union. The speaker believes the European Union is nastier than China and has treated the U.S. unfairly. However, the speaker asserts that the U.S. now holds all the cards and expects the European Union to concede.

The U.S. spends $1,126 per capita on drugs, while Britain spends about $240, roughly one-fifth of the U.S. amount, a trend seen across Europe. Drug companies claim America must pay for innovation. President Trump argues that European partners need to increase their drug payments to cover their share of innovation, asserting the U.S. will no longer subsidize them. If Europeans raise drug prices by 20%, $10 trillion could be spent on innovation, improving global health through better products.

Pharmaceutical companies generate over two-thirds of their profits in the United States, despite the U.S. accounting for only 4% of the world's population. The speaker expresses respect for pharmaceutical companies and their leadership. They believe these companies successfully convinced people for many years that the existing system was fair, even though the reasons why were not well understood. The speaker claims to have figured out the reasons behind this.

Pharmaceutical companies claimed high R&D costs had to be borne solely by America, effectively subsidizing socialist healthcare systems in countries like Germany and the European Union. The speaker believes the European Union is "nastier than China" and has treated the U.S. unfairly, but predicts they will concede because the U.S. "has all the cards."

A businessman told the speaker that the same fat shot drug cost him $88 in London but $1,300 in New York. The drugs were identical, made in the same plant by the same company. The speaker discussed this with a representative from the drug companies, who admitted there was no justification for the price difference.

Politicians have long promised to eliminate the discrepancy between drug prices in the U.S. and Europe. This was a key issue for Bernie Sanders, but previous leaders haven't acted on it. Politicians make these promises knowing they likely won't have to fulfill them. The reason is that Congress is heavily influenced by the pharmaceutical industry. There is at least one pharmaceutical lobbyist for every congressman, senator, and Supreme Court member.

Over 100 members of Congress support a bill to fund Ozempic with Medicare at $1500 a month, and most have taken money from Novo Nordisk, the drug's manufacturer. Once approved for Medicare, it goes to Medicaid, and there's a push to recommend Ozempic for Americans as young as 6 for obesity, a condition claimed to be preventable and recently rare. With 74% of Americans obese, the cost of Ozempic prescriptions for all of them would be $3 trillion a year. Novo Nordisk's value is based on projected Ozempic sales to Americans, yet the Danish government recommends diet and exercise instead. For half the price of Ozempic, every American could receive regeneratively raised organic food and gym memberships. Congress is allegedly doing the bidding of Novo Nordisk instead of supporting American farmers and children because Novo Nordisk heavily funds medical research, the media, politicians, and medical schools.

The U.S. has the most expensive healthcare system globally, spending significantly more per person than any other nation, yet achieving poorer outcomes. Life expectancy ranks 49th worldwide, and infant mortality is 54th. Additionally, a higher number of people live with multiple chronic conditions compared to other wealthy countries. This situation is alarming, yet many find healthcare unaffordable.

We're paying too much for drugs compared to other countries, and existing laws make it hard to lower costs. The middlemen in the drug industry are profiting significantly without adding value. We're going to eliminate these middlemen to reduce drug prices to unprecedented levels. This topic dominated our discussions with executives and others involved.

Medicare overspent on dimethyl fumarate in 2022, paying $590 million for a drug I offer at $65 per prescription. This discrepancy highlights how Pharmacy Benefits Managers (PBMs) inflate drug costs to increase their profits. Medicare's PBM charged them $3,800 per prescription when the real price is only $65. This PBM price gouging cost Medicare $580 million on just this one drug. The solution is simple: eliminate PBM contracts to save money. Also, your insurance likely uses a PBM, overcharging you too. Check if you're overpaying for your medications at fourthparkpharmacy.com to use our price checker.

One breast cancer drug costs Americans over $16,000 per bottle. The same drug, from the same factory, manufactured by the same company, costs one-sixth the price in Australia. In Sweden, the identical product costs one-tenth the price.

A common asthma drug costs almost $500 in America, but less than $40 in The United Kingdom. The speaker highlights the significant price difference, noting one person paid a small amount for the same shot in the UK. The weight loss drug Ozempic costs 10 times more in The United States than in the rest of the developed world, according to the speaker, who questions the reason for this disparity.

Politicians have long promised to address the discrepancy between drug prices in the U.S. and Europe. This issue was central to Bernie Sanders' presidential campaigns. However, these promises were never fulfilled because Congress is heavily influenced by the pharmaceutical industry. There is at least one pharmaceutical lobbyist for every member of Congress, the Senate, and the Supreme Court.

Big food, big pharma, big chemicals get super wealthy. Right? What is the product of health care? It's a healthy body. If we take The US population and compare it to the world, we're at the very bottom when it comes to health, yet we spend the most for health care. Over $4,100,000,000,000 every single year.

Americans pay significantly more for prescription drugs than other countries, sometimes up to 10 times more. Pharmaceutical companies generate two-thirds of their profits in the U.S., effectively making Americans subsidize healthcare in other countries. The administration is introducing a "most favored nation" pricing model, ensuring the U.S. pays the lowest price available globally for drugs. For example, a breast cancer drug costing over $16,000 in the U.S. is a fraction of that price in Australia and Sweden. Similarly, an asthma drug costs almost $500 in the U.S. but less than $40 in the UK. The plan involves directing investigations into foreign nations that block drug products unless they accept low prices, and the U.S. will defend drug companies from unfair pricing demands. The administration aims to cut out middlemen and facilitate direct drug sales at the most favored nation price. If companies don't comply, the U.S. will use its trade powers and open the market to safe, legal drug imports.

The transcript centers on a critique of Democrats and the healthcare industry, framing the Capitol Hill hearing as evidence of a coordinated effort to undermine President Trump’s health care agenda. It asserts that Democrats and “the big insurance companies” are “combining forces to sabotage president Trump on Capitol Hill,” and claims this is exemplified by coverage and clips available on the speaker’s website and social media. Key points highlighted: - Democrats, Obamacare architects, and the pharmaceutical/insurance cartel are alleged to be “working in lockstep to block president Trump’s patient first health care agenda.” - Ahead of the hearing, the speaker says Loomer Unleashed warned how the proceedings would unfold, asserting that corporate health care executives aligned with Democrats against President Trump, Congressional Republicans, and the American people. - The speaker claims Democrats deployed Obama operatives—people featured on Barack Obama’s White House website—as “experts” on health care, alongside anti-Trump radical left activists who allegedly pretended to be health care experts, to blame Republicans for the health care crisis without addressing Obamacare’s effects. - Congressional Republicans, specifically Jason Smith and Randy Feenstra, are quoted as arguing that Democrats want to cast blame elsewhere because they do not accept responsibility for Obamacare, which the speakers say was always going to be a disaster. - A clip from Speaker 1 describes the hearing as “the first of more to come examining the entire health care sector.” The stated purpose is to question some of the largest health insurers about why costs are rising and how health care can be made more affordable for all Americans, asserting that Democrats in the majority previously ignored this issue. - The speaker claims that Americans are still struggling to afford basic care, with premiums “exploding” and patients being delayed and denied care “every day.” - The hearing is said to have shown that, instead of demanding accountability, a senior Democrat reassured CEOs with the statement, “it’s not your fault,” implying the Democrats’ recognition that costs rose under Obamacare. - The claim is reiterated that, after fifteen years of a Democrat-created health system under Obamacare, prices have “only gone up, not down.” The speaker indicates there is extensive video and article coverage of the hearing available online, including numerous clips and a summary article that highlights these points. The overall narrative portrays Obamacare as a disaster, accusing Democrats of avoidance of responsibility and of manipulating the hearing to deflect blame away from policy outcomes.